We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance

Results: 1-10 of 2,198

The antidote - September 2014
  • CMS Cameron McKenna
  • European Union, United Kingdom, USA
  • September 9 2014

Summer is nearly at an end and whilst corporate activity continued apace, including AbbVie acquiring Shire, Omega Pharma attracting acquisition

Royalties for revoked patents do not necessarily breach EU competition rules
  • Penningtons Manches LLP
  • European Union, Germany, USA
  • October 25 2016

It is hard to imagine that when Genentech signed a licence agreement in 1992 with Sanofi's predecessor, it could have foreseen the litigation storm

Universities abroad experiment with no-fee licensing to drive biotech partnerships
  • Shook Hardy & Bacon LLP
  • Canada, European Union, United Kingdom, USA, Australia
  • May 16 2013

Universities in Australia, Canada, Europe, and the United Kingdom have reportedly embraced a 2010 Glasgow University initiative under which companies

Dispelling the Myriad gene patent harmonization myth
  • Foley & Lardner LLP
  • Australia, Canada, European Union, France, Germany, Japan, USA
  • April 30 2013

In the wake of the Supreme Court oral arguments in the Myriad "gene patent" case, most commentators are predicting that the Court will uphold the

Biological deposits and priority
  • Marks & Clerk
  • European Union, USA
  • April 23 2013

As a result of decision T010709, issued by an EPO Technical Board of Appeal on 12 July 2012, practitioners outside Europe and especially in the US

Kartellrechtliche fallstricke im life science-bereich
  • Baker McKenzie
  • European Union, France, USA
  • May 24 2013

Im Wettbewerb gegen Generika ist Vorsicht geboten: Verschiedene Maßnahmen gegen den Markteintritt kostengünstigerer Generika werden

November 2016 International Trade Compliance Update
  • Baker McKenzie
  • Africa, Asia-Pacific, Canada, Central & South America, Russia, South Korea, Ukraine, United Kingdom, USA, Democratic Republic of Congo, European Union, Global, Middle East, Myanmar, OECD
  • November 1 2016

Welcome to the November 2016 edition of Baker & McKenzie's International Trade Compliance Update. Here are some highlights: WTO: Trade policy reviews

FDA and European Medicines Agency to do parallel evaluation of new drug marketing applications
  • Hodgson Russ LLP
  • European Union, USA
  • April 4 2011

FDA is always criticized and questioned about taking longer to approve regulated products than its counterpart agency in Europe, European Medicines Agency (EMA

A comparison of US and EU biosimilars regimes
  • Fenwick & West LLP
  • European Union, USA
  • January 20 2012

Economic barriers, along with regulatory complexity and uncertainty, are shaping the biosimilars industry into something entirely different from the generic small molecule pharmaceutical industry

Privacy & Cybersecurity Update October 2016
  • Skadden Arps Slate Meagher & Flom LLP
  • European Union, USA
  • November 1 2016

In this edition of our Privacy & Cybersecurity Update, we take a look at the FCC's new rules for broadband privacy, the FTC's new playbook for data